791 related articles for article (PubMed ID: 26386686)
1. Ulcerative Colitis: Update on Medical Management.
Iskandar HN; Dhere T; Farraye FA
Curr Gastroenterol Rep; 2015 Nov; 17(11):44. PubMed ID: 26386686
[TBL] [Abstract][Full Text] [Related]
2. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
3. Vedolizumab for the treatment of ulcerative colitis.
Stallmach A; Schmidt C; Teich N
Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
[TBL] [Abstract][Full Text] [Related]
4. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
Tsai HH; Black C
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
[TBL] [Abstract][Full Text] [Related]
5. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
7. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
8. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
Bressler B; Marshall JK; Bernstein CN; Bitton A; Jones J; Leontiadis GI; Panaccione R; Steinhart AH; Tse F; Feagan B;
Gastroenterology; 2015 May; 148(5):1035-1058.e3. PubMed ID: 25747596
[TBL] [Abstract][Full Text] [Related]
9. The role of integrin antagonists in the treatment of inflammatory bowel disease.
Beniwal-Patel P; Saha S
Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
[TBL] [Abstract][Full Text] [Related]
10. Biologic Therapy for Ulcerative Colitis.
Bhattacharya A; Osterman MT
Gastroenterol Clin North Am; 2020 Dec; 49(4):717-729. PubMed ID: 33121691
[TBL] [Abstract][Full Text] [Related]
11. The role of biologics in the treatment of patients with inflammatory bowel disease.
Selinger CP; Carbery I; Al-Asiry J
Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
[TBL] [Abstract][Full Text] [Related]
12. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
13. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
Paschos P; Katsoula A; Salanti G; Giouleme O; Athanasiadou E; Tsapas A
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1174-1185. PubMed ID: 30378141
[TBL] [Abstract][Full Text] [Related]
14. Contemporary Management of Ulcerative Colitis.
Vanga R; Long MD
Curr Gastroenterol Rep; 2018 Mar; 20(3):12. PubMed ID: 29589185
[TBL] [Abstract][Full Text] [Related]
15. Positioning Therapy for Ulcerative Colitis.
Grinspan A; Kornbluth A
Curr Gastroenterol Rep; 2015 Aug; 17(8):29. PubMed ID: 26143627
[TBL] [Abstract][Full Text] [Related]
16. An approach to acute severe ulcerative colitis.
Sedano R; Quera R; Simian D; Yarur AJ
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):943-955. PubMed ID: 31648574
[No Abstract] [Full Text] [Related]
17. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
19. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
Pouillon L; Van Stappen J; Bossuyt P; Danese S; Peyrin-Biroulet L
Best Pract Res Clin Gastroenterol; 2018; 32-33():17-25. PubMed ID: 30060934
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics].
Bae JH; Yang DH
Korean J Gastroenterol; 2018 Apr; 71(4):192-195. PubMed ID: 29684967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]